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We report here on the diagnosis and successful treatment of a case of hairy cell leukemia (HCL) that arose 15 years
after kidney transplantation in a 51-year-old patient. As soon as the diagnosis was made, HCL was treated with
2-CDA, obtaining complete hematological remission. Immunosuppression with the calcineurin inhibitor cyclosporin
was maintained, and the graft was preserved. In kidney transplant recipients supported with immunosuppressive
drugs, post-transplant lymphoproliferative diseases (PTLDs) are frequent and typically related to immunosuppression
via a loss of control of infectious/EBV-related proliferative stimuli. To date, HCL has not been considered among
PTLDs. Recently, however, the oncogenic mutation V600E of the BRAF protein kinase has been found to be a
hallmark of HCL, and calcineurin inhibitors have been shown to interfere with signaling downstream of V600E BRAF
early on by counteracting senescence-associated mechanisms that protect against the oncogenic potential of the
mutated kinase. Such a biochemical link between the oncogene-dependent signaling and calcineurin inhibitor
activities suggests that HCL in transplanted patients might be a peculiar type of PTLD based on the presence of a
specific mutation. This mechanism might also be involved in other neoplasias bearing the same or similar
mutations, such as melanoma and non-melanoma skin cancer.
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Renal transplantation has been a major breakthrough in
the treatment of end-stage renal disease, improving quality
of life and reducing the mortality risk for most patients
when compared with maintenance dialysis [1]. However,
the rate of late graft loss remains excessive (10-year sur-
vival approximately 50%), primarily due to cardiovascular
diseases and neoplasias [2,3].
Kidney transplant recipients supported with immuno-
suppressive drugs are approximately three times more
likely to develop cancers than the general population. This
excess risk is 200 and 9–20 times for Kaposi's sarcoma and
nonmelanocytic/melanocytic skin cancer, respectively [4,5].
Among nonskin cancers, viral infection-related forms are
predominant, such as cervical in situ disease, vulvovaginal
disease, and the so-called post-transplantation lympho-
proliferative diseases (PTLDs), which include Epstein-* Correspondence: fabrizio.vinante@univr.it
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reproduction in any medium, provided the orBarr virus-driven B-cell lymphoproliferation, Hodgkin's
lymphoma, multiple myeloma, T/natural killer-cell lym-
phoproliferation, hepatosplenic γδ T-cell lymphoma and
virus-induced hemophagocytic syndrome [5-7]. Hairy cell
leukemia (HCL) is a rare indolent B-cell lymphopro-
liferative disease that induces severe, life-threatening pan-
cytopenia and is not currently considered a PTLD. One
case of HCL, which caused the patient’s death, has been
reported following renal transplantation [8], and one other
case has been reported in a heart transplant patient [9].Case presentation
A 51-year-old female was admitted to our renal unit with
an 8-week history of severe neutropenia mild anemia and
thrombocytopenia. She underwent a cadaveric kidney
transplant in 1998 after 2 years of hemodialysis treatment
for end-stage renal disease due to chronic tubular-
interstitial nephritis. Following transplant, renal function
was stable over 15 years with serum creatinine ranging
from 106 to 133 μmol/L and no significant daily protein-
uria. Maintenance immunosuppressive therapy includedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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methylprednisolone (MP, 4 mg/day) and mycophenolate
mofetil (MMF, 1 g/day). MP and MMF were discontinued
due to neutropenia, but CsA was maintained.
A physical examination, renal allograft function, abdom-
inal ultrasonography, thoracic Rx and rheumatologic and
infectious disease screening were unremarkable. Because
the pancytopenia was persistent, peripheral blood and
bone marrow examinations were performed. A peripheral
blood smear and a flow cytometric study of circulating
mononuclear cells failed to show diagnostic cells. Bone
marrow could not be aspirated. Biopsy showed severely
hypocellular marrow with few infiltrating B cells, which
suggested lymphoproliferative disease. A contralateral
biopsy showed a pattern of marrow infiltration by mature
B lymphocytes that was diagnostic of HCL (Figure 1).
The severely neutropenic patient was supported with
both G-CSF and Epo and underwent ambulatory chemo-
therapy with the purine analog 2-CDA (2-Chlorodeoxya-
denosine, leustatin, cladribine) according to a schedule of
0.1 mg/Kg IV once per week for 4 to 6 weeks. Prophylaxis
with sulfamethoxazole-trimethoprim and recommended
adequate hydration with crystalloids were performed. The
2-CDA schedule was continued for up to 6 administrations
without adverse reactions or infectious complications. Due
to an increase in serum creatinine to 199 μmol/L, the
fourth administration was delayed one week, and the entire
course of therapy lasted 7 weeks. Blood counts reached
normal values approximately 2 months after starting 2-
CDA. Currently, one year after stopping treatment, the
patient is in continuous complete hematological remissionFigure 1 Bone marrow biopsy. Infiltrate of mature lymphoid cells (hema
and V600E BRAF (HCL markers). Histology and immunohistology were perfowith stable renal function (Figure 2). No bone marrow
evaluation was performed.
Discussion
Approximately 2% of leukemias in the general popula-
tion are HCLs, with fewer than 2,000 new cases diag-
nosed annually in North America and Western Europe
combined, and the disease occurs predominantly in
older males [10]. After its characterization by Bouroncle
and colleagues in 1958 [11], HCL was named after the
“hairy” projections observed microscopically on the ma-
lignant mature B cells.
Hairy cells progressively infiltrate the bone marrow
and spleen, and mild to severe pancytopenia and spleno-
megaly are frequent features at diagnosis. Although a
full-blown leukemic picture is sometimes observed, only
scant hairy cells are typically observed in the peripheral
blood. High levels of soluble p55-IL-2R [12] and TNFRs
[13], shed by the neoplastic cells, are detectable in the
serum. TNF appears to play a pathogenic role [14]
reminiscent of that in other leukemias [15,16]. Before
the introduction of effective therapy, the median survival
was approximately 50 months, and the natural history of
HCL was one of progressive splenomegaly, bone marrow
failure and death, typically due to infection. Alpha-
interferon was the first treatment to obtain full remis-
sion of disease [12]. Subsequently, a variety of systemic
agents have been used. 2-CDA is the preferred front-line
therapy to date and is capable of inducing durable
clinical remission in the majority of cases, although it
fails to be curative [17,18].toxylin & eosin, H/E), which stained for CD20 (B cell marker), DBA44
rmed according to standard diagnostic procedures.
Figure 2 Sequential hemochrome and creatinine values in
relationship to treatment.
Vinante et al. Experimental Hematology & Oncology 2013, 2:22 Page 3 of 5
http://www.ehoonline.org/content/2/1/22Due to deep neutropenia and monocytopenia (Figure 2),
HCL patients are prone to life-threatening infections, in-
cluding atypical mycobacteriosis and aspergillosis. Thereare two relevant risks with HCL in transplant patients:
life-threatening sepsis due to severe neutropenia and
immunosuppression and the risk of graft loss due to either
sepsis or deferred immunosuppression. Therefore, we
started treatment early after diagnosis [18]. Erythropoietin
and granulocyte colony stimulating factor allowed for the
maintenance of adequate hemoglobin and white blood cell
counts and most likely made it easier to avoid infection
and complete the entire course of therapy with 2-CDA.
We maintained CsA to preserve the transplant.
The pathogenesis of post-transplantation malignancies
appears to be related to immunosuppression, leading
to impaired immune activity against viruses, impaired
immunosurveillance of neoplastic cells, DNA damage
and disruption of DNA repair mechanisms and the
upregulation of cytokines that can promote tumor
progression (e.g., TNF, TGFβ, IL-10, VEGF). HCL is not
currently considered a post-transplantation malignancy
related to immunosuppression [19], but a coincidental
event in a transplant patient.
Recently, however, the V600E mutation of the BRAF
kinase protein (Figure 1), previously described in moles
[20], melanoma and other cancers [21,22], has been
recognized to be present in the majority of typical HCL
cases [23]. The mutation results in the constitutive
activity of BRAF kinase, which in turn triggers the Ras
pathway, AP-1 and NFAT to promote cell growth
[22,24]. Constitutively activated BRAF may trigger senes-
cence, which neutralizes the mitogenic potential of BRAF
[20]. Secondary events, however, may restore the full
mitogenic potential of BRAF and induce lesion progres-
sion to overt cancer [20,25,26]. Calcineurin inhibitors such
as CsA and tacrolimus participates in the BRAF pathway,
and reduce the amount of message converging on NFAT
downstream mutated BRAF [24,27-30]. By doing this,
calcineurin inhibitors may counteract V600E BRAF-
dependent senescence and increase the tumorigenic
potential of senescent lesions [20,25,26,31].
Therefore, HCL harbors a mutated form of BRAF
protein kinase [23] that results in constitutive signaling
involved in oncogenesis [20,21,26-32], and calcineurin
inhibitors play a part in this signaling [21,22,24-34]. This
direct link between immunosuppression and a typical
oncogenic feature of HCL may suggest that HCL could
be considered a PTLD instead of a merely coincidental
event in a host treated with calcineurin inhibitors, al-
though it may be a peculiar PTLD entailing the V600E
BRAF protein kinase mutation and most likely additional
events [20,25,26,31].
Paradoxically, calcineurin inhibitors may also counter-
act the constitutive BRAF-driven mitogenic activity in
overt cancer [25,28-31], based on the same biochemical
mechanism [24,25,31,32]. Therefore, inhibitors of BRAF
signaling may have the opposite effects depending on
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[20,25,26] or cancerous [28-30,32-34]. This duality may
explain why melanomas harboring the V600E mutation
of BRAF are quite frequent in transplant patients
immunosuppressed with calcineurin inhibitors [4,5,21] as
well as why BRAF inhibitors may have a place in melano-
ma treatment [21,27,30-34].
Our results suggest the following conclusions: 1) Persis-
tent pancytopenia in a transplant patient requires timely
and thorough consideration. 2) HCL should be treated as
soon as possible in transplanted patients, and 2-CDA may
be a good therapeutic option to induce disease remission
and avoid life-threatening infection and graft loss. 3) The
occurrence of a direct link between oncogenic pathways
and calcineurin inhibitors in V600E BRAF-bearing cells
may perhaps suggest that HCL could be included among
PTLDs, although HCL might be a peculiar PTLD based
on the presence of a specific mutation. 4) In general,
immunosuppressive drugs may target mutation-activated
oncogenic pathways to promote cancer.
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